Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324089 · ClinicalTrials.gov registry record · NA
Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01324089: Completed NA study, sponsored by University of Wisconsin, Madison.
NCT01324089 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01324089, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
There is some evidence that when resveratrol (a substance which is found in red grapes, peanuts and chocolate) is combined with Piperine (a substance found in pepper) it is more effective in fighting cancer. The purpose of this study is to see if resveratrol in combination with piperine is more effective than taking resveratrol alone. Since investigators don't know what dose of piperine to use in combination with resveratrol, two different doses of piperine will be studied. Twenty-four participants, equal numbers of males and females, will receive a single dose of resveratrol (2.5 grams) without piperine, resveratrol (2.5 grams) with piperine (5 mg), or resveratrol (2.5 grams) with piperine (25 mg).
Primary Outcome
Blood levels of Resveratrol/Piperine will be measured
Interventions
- DIETARY_SUPPLEMENT Resveratrol
- DIETARY_SUPPLEMENT Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
- DIETARY_SUPPLEMENT Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-03 |
| Phase | NA |
What the finished NCT01324089 record still lists
NCT01324089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Resveratrol is the first listed.
NCT01324089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01324089 about?
NCT01324089 is a clinical study titled "Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol". There is some evidence that when resveratrol (a substance which is found in red grapes, peanuts and chocolate) is combined with Piperine (a substance found in pepper) it is more effective in fighting cancer. The purpose of this study is to see if resveratrol in combination with piperine is more effe...
What is the current status of trial NCT01324089?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2011-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01324089?
The interventions under investigation include: Resveratrol (DIETARY_SUPPLEMENT), Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose (DIETARY_SUPPLEMENT), Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01324089?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01324089's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia